Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,761.00
Bid: 1,757.50
Ask: 1,758.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.028%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,761.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET PRE-OPEN: Bunzl raises dividend after strong results

Tue, 31st Aug 2021 07:48

(Alliance News) - Stock prices in London are seen opening higher on Tuesday after being closed on Monday for the long holiday weekend, as investors responded positively to cautious signals from the US Federal Reserve.

In early company news, drugmaker GlaxoSmithKline said it has started late-stage trials for a Covid-19 vaccine. Distribution firm Bunzl reported positive interim results and made further acquisitions. IT services provider Computacenter issued an upbeat trading statement.

IG futures indicate the FTSE 100 index is to open 20.29 points higher at 7,168.30. The blue-chip index closed up 23.03 points, or 0.3%, at 7,148.01 on Friday.

GlaxoSmithKline and its South Korean partner SK bioscience said they have started a phase 3 clinical study of SK's Covid-19 vaccine candidate GBP510 after positive interim phase 1 and 2 results.

Glaxo said the randomised, active-controlled global trial will enrol around 4,000 participants from a range of countries and will aim to evaluate GBP510's safety and immunogenicity compared the AstraZeneca/Oxford University Covid-19 vaccine. The study will be one of the first global phase 3 trials to compare two different Covid-19 vaccine candidates.

GBP510 is a self-assembled nanoparticle vaccine candidate targeting the receptor binding domain of the SARS-CoV-2 Spike protein, combined with Glaxo's pandemic adjuvant technology, Glaxo explained.

Separately, Glaxo is working with mRNA specialist, CureVac, to jointly develop next generation, optimised mRNA vaccines for Covid-19 with the potential to address multiple emerging variants in one vaccine.

Results from the phase 3 study are expected in the first half of 2022 after which, subject to positive results and regulatory approval, the vaccine is expected to be supplied at scale worldwide through the COVAX facility. No safety concerns have been identified to date in the ongoing study, Glaxo added.

Bunzl reported a rise in first half profit which the distribution firm attributed to the resilience of its diversified portfolio, despite pointing to an easing of Covid-19 related sales.

During the pandemic, Bunzl has benefitted from distributing Covid-19 personal protective equipment to businesses.

For the six months that ended June 30, revenue was GBP4.87 billion, up 0.4% from GBP4.85 billion last year and pretax profit was GBP275.7 million, up 12% from GBP245.4 million.

Bunzl declared an interim dividend of 16.2 pence, up 2.5% from 15.8p paid out last year.

Separately, Bunzl said it completed two further acquisitions. In July, Bunzl completed the acquisition of Proin Pinilla, the largest independent safety distributor to end-users in Spain, with a focus on personal protection equipment and specialising in workwear. The business generated GBP15 million of revenue in 2020, it said. In addition, Bunzl completed the acquisition of Arprosa in July, which also distributes PPE to end-users in Spain. The business generated GBP7 million of revenue in 2020.

Chief Executive Officer Frank van Zanten said: "One of the key strengths of our decentralised business is the ability to respond to local situations, enabling a consistent focus on delivering the right solutions for our customers. Whilst we are now seeing a reversal in Covid-19 related sales, this has been more than offset by the recovery experienced in our base business over the first half. The group's performance over the first half and the excellent underlying revenue growth we have delivered over a two year period demonstrate the resilience of our diversified portfolio.

"Our outlook for 2021 is unchanged and we continue to expect, at constant exchange rates, underlying revenue to be moderately higher than the pre-pandemic period in 2019. Looking ahead, we expect future growth to be supported by a recovery in the base business and economic activity, enhanced hygiene trends and our differentiated offering of sustainable and responsible solutions."

Computacenter said trading has continued to be robust across all of of its geographies in July and August to date.

The computer services provider said the "exceptionally good performance" in the second half of 2020 makes a more difficult comparison than it experienced in the first half of this year.

However, even with a flat performance in the second half of 2021 compared to the second half of last year, the company said it would finish the year 10% ahead of current market expectations for the group's full year 2021 adjusted pretax profit. It posted adjusted pretax profit of GBP200.5 million in 2020.

"Whilst visibility in our business is never perfect, given the momentum in the business, a substantial order backlog, the successful acquisitions and a strong forecast we will endeavour to beat last year's second half performance, not just match it," the company said.

In the US on Monday, Wall Street ended mostly higher, with the Dow Jones Industrial Average down 0.2%, S&P 500 up 0.4% and Nasdaq Composite up 0.9%.

Last week, Fed Chair Jerome Powell said the central bank could be ready to slow the pace of its colossal bond-buying program this year, but would be patient about raising the benchmark interest rate while watching for the impact of the Delta variant and the labour market's recovery.

The Japanese Nikkei 225 index closed up 1.1%. In China, the Shanghai Composite was down 0.2%, while the Hang Seng index in Hong Kong was down 0.6%. The S&P/ASX 200 in Sydney ended up 0.4%.

China's services sector contracted in August for the first time since the start of the pandemic while factory activity slowed further, data showed, as domestic coronavirus travel curbs hit demand for transport and tourism.

The non-manufacturing purchasing managers' index, a key gauge of activity in China's services and construction sectors, fell to 47.5 in August from July's 53.3, the National Bureau of Statistics said.

The measure for factory activity, manufacturing PMI, came in at 50.1 in August from July's 50.4. Anything above 50 indicates expansion, while below that figure points to contraction.

China's economic recovery was dealt a blow in the summer by its largest coronavirus outbreak for months as authorities locked down millions and curbed travel during the peak summer tourism period.

AvaTrade analyst Naeem Aslam said: "Futures in the US and Europe are trading higher today as investors appear to be more optimistic regarding the performance of equity markets. There are two reasons for this. First, the dovish stance taken by Jerome Powell, the chair of the Federal Reserve, last week conveyed that interest rates would not be raised immediately after stimulus tapering and would only be changed once the economy is near full employment with inflation in check.

"Second, the excellent earnings achieved by companies have provided valuation support, which has become the foundation supporting the surge in stock prices."

The pound was quoted at USD1.3793 early Tuesday, up from USD1.3752 at the London equities close Friday.

The euro stood at USD1.1825, up from USD1.1788. Against the yen, the dollar was trading at JPY109.80, down from JPY109.92.

Brent oil was quoted at USD73.19 a barrel, up from USD72.28 at the London equities close Friday. Gold was trading at USD1,816.85 an ounce, higher against USD1,807.81.

On Tuesday, there is German unemployment at 0855 BST and eurozone inflation at 1000 BST.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
31 Jan 2024 09:13

TOP NEWS: GSK profit up on Arexvy boost in 2023 but total payout down

(Alliance News) - GSK PLC reported an increase in profit and revenue for 2023 as revenue for HIV medicine had stable growth, amid optimism in the company's outlook.

Read more
31 Jan 2024 08:55

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

Read more
31 Jan 2024 07:46

LONDON BRIEFING: Stocks called up; GSK revenue and profit up

(Alliance News) - Stocks in London are called to open higher, as markets share of nerves around the next set of interest rate decisions.

Read more
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more
26 Jan 2024 10:47

Citi hikes target price for GSK but stays 'neutral'

(Sharecast News) - Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1,535p to 1,700p.

Read more
24 Jan 2024 15:08

Private equity firm Yellow Wood close to deal to acquire ChapStick-sources

Jan 24 (Reuters) - Private equity firm Yellow Wood Partners is in advanced talks to acquire ChapStick, a lip balm brand, from Haleon Plc, the former consumer health division of drug developer GSK Plc, four people familiar with the matter said.

Read more
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.